Last reviewed · How we verify
NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Prevacid | lansoprazole | Generic (originally Takeda) | Proton pump inhibitor (PPI) | ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase | 1995-05-10 | |
| Prevacid | Prevacid | Vanderbilt University Medical Center | ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Takeda) · 1 drug in NSAID-Induced Gastric Ulcer
- Vanderbilt University Medical Center · 1 drug in NSAID-Induced Gastric Ulcer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in NSAID-Induced Gastric Ulcer:
- NSAID-Induced Gastric Ulcer treatment updates — RSS
- NSAID-Induced Gastric Ulcer treatment updates — Atom
- NSAID-Induced Gastric Ulcer treatment updates — JSON
Cite this brief
Drug Landscape (2026). NSAID-Induced Gastric Ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nsaid-induced-gastric-ulcer. Accessed 2026-06-10.
Related
- NSAID-Induced Gastric Ulcer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing